Ask AI
ProCE Banner Activity

CAR-T Bridging, Sequencing, and Care Coordination Considerations in RRMM

Slideset

CAR T-cell therapy is transforming outcomes for patients with multiple myeloma (MM), but rapid uptake has also introduced new, high-stakes complexity in day-to-day care. In this downloadable teaching resource, you will find expert-led information regarding hot topics in the practical implementation of CAR T-cell in MM. Topics covered include the rationale for using CAR T-cell in MM, patient selection, current and future considerations for sequencing, bridging strategies, and key adverse event recognition strategies. 

Released: August 17, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by educational grants from Johnson & Johnson and Legend Biotech USA Inc.

Johnson & Johnson

Legend Biotech USA Inc.

Target Audience

This activity is intended for hematologists, oncologists, advanced practice providers, nurses, pharmacists, and other healthcare professionals who care for patients with multiple myeloma. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply patient selection and eligibility criteria for BCMA-directed CAR-T therapy in MM, including evidence-informed considerations for high-risk disease, older or frail patients, and those with clinically relevant comorbidities 

  • Implement bridging and sequencing strategies across BCMA CAR-T and T-cell–redirecting therapies (including bispecific antibodies), using emerging clinical trial and real-world evidence to optimize timing, target selection, and downstream options 

  • Integrate new and evolving BCMA CAR-T data, including earlier-line use, durability of response, and real-world experience, into practical, patient-specific treatment decisions

  • Recognize, differentiate, and manage CAR-T–associated adverse events, with emphasis on CRS and ICANS, as well as late/atypical neurotoxicities reported with BCMA-directed constructs (eg, Parkinsonian features and cranial nerve palsies), to support timely triage and safe care delivery